Exelixis (EXEL) Capital Expenditures (2010 - 2026)
Exelixis (EXEL) recorded quarterly Capital Expenditures of $1.5 million in Q2 2026, up 30.42% quarter-over-quarter from $1.2 million in Q1 2026, and down 48.88% on a YoY basis from $3.0 million in Q2 2025.
Exelixis (EXEL) Capital Expenditures (2010 - 2026) Analysis & Trends
Exelixis' Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.5 million for Q2 2026.
- In Q2 2026, Capital Expenditures fell 48.88% year-over-year to $1.5 million; the TTM figure through Apr 2026 stood at $7.0 million (down 67.8% YoY), while the FY2026 annual figure was $8.4 million, down 70.36% from the prior year.
- Capital Expenditures was $1.5 million for Q2 2026 at Exelixis, up from $1.2 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $13.1 million in Q4 2023 to a low of $1.2 million in Q1 2026.
- Historically, Capital Expenditures has averaged $6.3 million across 5 years, with a median of $5.9 million in 2023.
- Biggest YoY gain for Capital Expenditures was 187.01% in 2022; the steepest drop was 88.31% in 2022.
- A 5-year view of Capital Expenditures shows it stood at $9.7 million in 2022, then soared by 35.18% to $13.1 million in 2023, then slumped by 37.59% to $8.2 million in 2024, then tumbled by 81.92% to $1.5 million in 2025, then gained by 1.82% to $1.5 million in 2026.
- The last three Capital Expenditures figures came in at $1.5 million (Q2 2026), $1.2 million (Q1 2026), and $1.5 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -63,220.27 |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | 1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 1.51 Mn |
| Apr 3, 2026 | 1.51 Mn |
| Jan 2, 2026 | 1.16 Mn |
| Jan 2, 2026 | 1.16 Mn |
| Oct 3, 2025 | 1.48 Mn |
| Oct 3, 2025 | 1.48 Mn |
| Jul 4, 2025 | 2.84 Mn |
| Jul 4, 2025 | 2.84 Mn |
| Apr 4, 2025 | 2.95 Mn |
| Apr 4, 2025 | 2.95 Mn |
| Jan 3, 2025 | 3.98 Mn |
| Jan 3, 2025 | 3.98 Mn |
| Sep 27, 2024 | 8.20 Mn |
| Sep 27, 2024 | 8.20 Mn |
| Jun 28, 2024 | 6.57 Mn |
| Jun 28, 2024 | 6.57 Mn |
| Mar 29, 2024 | 9.69 Mn |
| Mar 29, 2024 | 9.69 Mn |
| Dec 29, 2023 | 13.14 Mn |
| Dec 29, 2023 | 13.14 Mn |